Numerous studies have described how the TCR and BCR repertoires are altered in the context of certain infections, malignancies or immunological disorders.33,37–39 The emergence of specific TCR clonotypes or of an oligoclonal/monoclonal-skewed TCR repertoire is an important immunological ‘signature’.34 Recently, Thorsson et al.35 extensively analyzed TCR and BCR repertoires from RNA-seq data of various cancer types from The Cancer Genome Atlas cohort. Here, BCR is linked to cancer.